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Body-mass index and cause-speciﬁ c mortality in 
900 000 adults: collaborative analyses of 57 prospective 
studies
Prospective Studies Collaboration*
Summary
Background The main associations of body-mass index (BMI) with overall and cause-speciﬁ c mortality can best be 
assessed by long-term prospective follow-up of large numbers of people. The Prospective Studies Collaboration aimed 
to investigate these associations by sharing data from many studies.
Methods Collaborative analyses were undertaken of baseline BMI versus mortality in 57 prospective studies with 
894 576 participants, mostly in western Europe and North America (61% [n=541 452] male, mean recruitment age 
46 [SD 11] years, median recruitment year 1979 [IQR 1975–85], mean BMI 25 [SD 4] kg/m²). The analyses were 
adjusted for age, sex, smoking status, and study. To limit reverse causality, the ﬁ rst 5 years of follow-up were excluded, 
leaving 66 552 deaths of known cause during a mean of 8 (SD 6) further years of follow-up (mean age at death 
67 [SD 10] years): 30 416 vascular; 2070 diabetic, renal or hepatic; 22 592 neoplastic; 3770 respiratory; 7704 other.
Findings In both sexes, mortality was lowest at about 22·5–25 kg/m². Above this range, positive associations were 
recorded for several speciﬁ c causes and inverse associations for none, the absolute excess risks for higher BMI and 
smoking were roughly additive, and each 5 kg/m² higher BMI was on average associated with about 30% higher 
overall mortality (hazard ratio per 5 kg/m² [HR] 1·29 [95% CI 1·27–1·32]): 40% for vascular mortality (HR 
1·41 [1·37–1·45]); 60–120% for diabetic, renal, and hepatic mortality (HRs 2·16 [1·89–2·46], 1·59 [1·27–1·99], and 
1·82 [1·59–2·09], respectively); 10% for neoplastic mortality (HR 1·10 [1·06–1·15]); and 20% for respiratory and for all 
other mortality (HRs 1·20 [1·07–1·34] and 1·20 [1·16–1·25], respectively). Below the range 22·5–25 kg/m², BMI was 
associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and 
lung cancer. These inverse associations were much stronger for smokers than for non-smokers, despite cigarette 
consumption per smoker varying little with BMI.
Interpretation Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add 
extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and 
below the apparent optimum of about 22·5–25 kg/m². The progressive excess mortality above this range is due 
mainly to vascular disease and is probably largely causal. At 30–35 kg/m², median survival is reduced by 2–4 years; at 
40–45 kg/m², it is reduced by 8–10 years (which is comparable with the eﬀ ects of smoking). The deﬁ nite excess 
mortality below 22·5 kg/m² is due mainly to smoking-related diseases, and is not fully explained.
Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, EU BIOMED programme, 
US National Institute on Aging, and Clinical Trial Service Unit (Oxford, UK). 
Introduction
Body-mass index (BMI) is a reasonably good measure 
of general adiposity,1 and raised BMI is an established 
risk factor for several causes of death, including 
ischaemic heart disease,2 stroke,3 and cancers of 
the large intestine, kidney, endometrium, and post-
menopausal breast.4,5 In many populations, the average 
BMI has been rising by a few percent per decade,6 
fuelling concern about the eﬀ ects of increased adiposity 
on health. Some uncertainties persist, however, about 
the relation between BMI and mortality, including 
whether some of the reported positive or inverse 
associations have been distorted by weight loss because 
of pre-existing disease (reverse causality) or by 
inadequate control for the eﬀ ects of smoking; whether 
the shape and strength of associations with speciﬁ c 
diseases diﬀ er between smokers and non-smokers; how 
the relative and absolute risks for BMI compare with, 
and also combine with, those for smoking; whether the 
relative risks diﬀ er much by sex or age (and whether 
any substantial association continues into old age7); 
how the absolute excess risks for vascular disease 
compare with those for neoplastic or respiratory disease; 
and the extent to which some less common causes of 
death, such as kidney8 or liver9 disease, are associated 
with BMI.
Some of these uncertainties can best be addressed by 
large prospective observational studies—or by large 
collaborative analyses of individual data from such 
studies, as in this report—that follow up generally 
healthy adults for many years and identify large 
numbers of deaths from speciﬁ c causes. In the 
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Prospective Studies Collaboration (PSC), the investi-
gators of 61 prospective studies have shared individual 
data for a million adults.10,11 The collaboration was 
established chieﬂ y to assess the relevance of blood 
pressure10 and blood cholesterol11 to cause-speciﬁ c 
mortality, but for 57 of the studies information was also 
available for BMI (although generally not for waist 
circumference). This PSC report examines the relevance 
of BMI to cause-speciﬁ c mortality 5 or more years after 
recruitment into these studies.
Methods 
Data collection
Previous PSC reports10,11 have described the methods of 
study selection, data collection, and statistical analysis, 
and similar methods were used in this report. BMI was 
calculated as weight in kg divided by the square of 
height in m. In three studies of US health professionals, 
height and weight were self-reported by participants. 
Following WHO convention, BMI of 30 kg/m² or more 
is termed obese. Individuals with missing data for age, 
sex, or BMI were excluded, as were those with BMI less 
than 15 kg/m² (188 excluded) or 50 kg/m² or more (297), 
those with a baseline history of heart disease 
(54 347) or stroke (4349), and those with no follow-up 
in the age range 35–89 years (25 949), leaving 
894 576 parti cipants. Information about blood pressure 
(882 032) and total cholesterol (814 109) was available 
for most participants, as was information about tobacco 
smoking (849 723) and diabetes mellitus (698 255). 
Information was, however, available for relatively few 
of the participants about alcohol drinking (297 584), 
HDL cholesterol (114 939), and LDL cholesterol (42 937). 
Of current drinkers, 78% (155 900) had information 
about grams of alcohol consumed per day, and of 
current cigarette smokers, 57% (166 724) had information 
about daily number of cigarettes smoked. 
Generally, the underlying cause of death was obtained 
from the death certiﬁ cate (information about 
contributory causes was not available), but in many 
studies conﬁ rmation was then sought from other 
sources, such as medical records and autopsy ﬁ ndings. 
The cause of death was coded to 3 digits using any of 
International Classiﬁ cations of Diseases (ICD) 6–10.
Statistical analysis
Cross-sectional associations between BMI and risk 
factors were estimated by multiple linear regression or 
logistic regression, with adjustment for study, baseline 
age (in 10-year groups), and baseline smoking (three 
groups: current cigarette smoker [32%]; never smoked 
any type of tobacco regularly [35%]; and other smoker, 
ex-smoker of any type of tobacco, or unknown [8%, 19%, 
and 5%, respectively]). Any individuals with missing 
values of BMI or the particular risk factor were excluded. 
Associations between baseline BMI and mortality were 
estimated by Cox regression, with stratiﬁ cation for study, 
sex, age at risk (in 5-year groups), and baseline smoking 
(as above), but not for blood pressure, blood lipids, or 
diabetes (since these are mechanisms by which BMI 
aﬀ ects vascular mortality). The resulting relative risks 
were not corrected for the regression dilution bias,12 since 
one BMI measurement is highly correlated with the 
long-term usual BMI (self-correlation 0·90 between 
baseline BMI and a re-measurement of BMI some 6 years 
later; webappendix p 11). In categorical analyses, the 
boundaries of BMI categories were always multiples of 
2·5 kg/m², and the boundaries used in particular analyses 
are indicated by tick marks in the ﬁ gures. Values exactly 
on a boundary went above it. In continuous analyses, log 
risk was regressed on BMI as a continuous variable 
within the range 15–25 kg/m² (termed the lower range), 
25–50 kg/m² (upper range), or 15–50 kg/m² (full range), 
yielding in each range the hazard ratio per 5 kg/m² 
higher BMI (HR). To limit eﬀ ects of pre-existing disease 
on baseline BMI, the main analyses exclude all 
person-years and deaths in the ﬁ rst 5 years of follow-up.
Relative risks for diﬀ erent BMI categories are presented 
as ﬂ oating absolute risks by multiplying all of them by a 
common constant to make their inverse-variance-weighted 
average match the uniformly age-standardised death rate 
per 1000 person-years at ages 35–79 years (ie, the simple 
mean of the nine age-speciﬁ c rates at ages 35–39 years to 
75–79 years) either in the PSC population, or in the 
European Union (EU) population in 2000 (ie, the combined 
population of 15 western European countries).13 Multi-
plication of all the relative risks by this common constant 
means that the ﬂ oating absolute risks (and the SEs of the 
log risks) do not depend at all on the choice of an arbitrary 
reference group. Hence, an appropriate SE and CI can be 
assigned to the log of the ﬂ oating absolute risk in each 
BMI category.14 This SE—described more simply as the 
SE of the log rate (Julian Peto, London School of Hygiene 
and Tropical Medicine, London, UK; personal com-
munication)—does not depend on the common constant 
that was chosen, and is roughly equivalent to the 
coeﬃ  cient of variation of the risk in that one group. 
The webappendix provides further information, in-
cluding details of the collaborating studies, endpoint 
deﬁ nitions, BMI re-measurement results, and ﬁ ndings 
for speciﬁ c causes of death.
Role of the funding sources
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. GW, PS, and SL had full access to 
the data in the study, and the writing committee had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
In the 57 studies with information for BMI, individual 
records with information about BMI were available for 
894 576 adults. 92% of these participants were in Europe, 
See Online for webappendix
For downloadable slides of all 
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Figure 1: Vascular risk factors 
versus BMI at baseline in the 
range 15–50 kg/m²
Adjusted for baseline age, 
baseline smoking status (apart 
from the smoking ﬁ ndings), 
and study. Numerical values are 
shown for 20–22·5 kg/m², for 
30–32·5 kg/m², and for the 
extreme BMI groups. 
Boundaries of BMI groups are 
indicated by tick marks. 
95% CIs are not shown, but 
most are narrower than the 
heights of the plotted symbols. 
(A) Blood pressure (in 
533 242 males 
and 348 790 females). 
(B) Blood cholesterol fractions 
(in 62 364 males and 
52 575 females with total and 
HDL cholesterol both 
measured); dashed line 
indicates the ratio of mean 
non-HDL cholesterol to mean 
HDL cholesterol (mean of the 
individual ratios would be 
about 8–12% greater). 
(C) Prevalences in males for 
alcohol drinking (168 283), 
cigarette smoking (334 496), 
and diabetes (378 854). 
(D) Prevalences in females for 
alcohol drinking (129 301), 
cigarette smoking (226 307), 
and diabetes (319 401). 
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Israel, the USA, or Australia; the remaining 8% 
(accounting for just 3% of the deaths) were in Japan. 85% 
(763 274) of participants were recruited during the 1970s 
or 1980s. Across all studies, median year of recruitment 
was 1979 (IQR 1975–85), mean recruitment age was 
46 (SD 11) years, and 61% (n=541 452) were male. Mean 
BMI was 24·8 (SD 3·8) kg/m², but it was lower in the 
European and Israeli studies (24·7 [3·6] kg/m²) than in 
the US and Australian studies (25·6 [4·3] kg/m²), and 
lower still in the Japanese studies (22·8 [2·9] kg/m²). 
For both sexes, mean BMI at baseline was greatest 
between 50 years and 69 years of age (webappendix p 11). 
For people with a re-measurement of BMI more than 
5 years after baseline, the rate of change between the two 
measurements showed an increase in BMI in early adult 
life and middle age (particularly in women), a levelling oﬀ  
in late middle age, and a slight decrease in old age 
(webappendix p 11). The greatest rate of increase (about 
1·5 kg/m² per decade) was in men younger than 40 years 
and women younger than 50 years. Apart from these 
age-related trends, the changes on re-measurement were 
slight, and were consistent with regression to the mean 
having had only a minor eﬀ ect that negated any even 
more minor tendency for usual BMI values to disperse 
(webappendix p 12).
At baseline, several vascular risk factors were strongly 
related to BMI (ﬁ gure 1). Throughout the full range 
(15–50 kg/m²), BMI was associated positively and nearly 
linearly with systolic and diastolic blood pressure (SBP, 
DBP; ﬁ gure 1A). On average across all ages (15–89 years), 
every 5 kg/m² higher BMI was associated with at 
least 5 mm Hg higher SBP (male 5·8 mm Hg, 
female 5·2 mm Hg) and about 4 mm Hg higher DBP 
(male 4·9 mm Hg, female 3·3 mm Hg). In the range up 
to 30 kg/m², BMI was associated inversely with HDL 
cholesterol (male 0·16 mmol/L, female 0·14 mmol/L  lower 
per 5 kg/m²), positively with non-HDL cholesterol (male 
0·50 mmol/L, female 0·39 mmol/L higher per 5 kg/m²), 
and therefore strongly positively with the ratio of 
non-HDL to HDL cholesterol (male 0·85, female 0·54 
higher ratio per 5 kg/m², from analyses of individual 
ratios: figure 1). These relations with blood pressure and 
with the non-HDL/HDL cholesterol ratio were about a 
third weaker in the 2% of participants aged 70–89 years 
(data not shown). Above 30 kg/m², BMI was only weakly 
associated with either cholesterol fraction (ﬁ gure 1B). 
Obesity was strongly associated with diabetes 
(ﬁ gures 1C and 1D), with the sex-speciﬁ c prevalences 
rising more than ﬁ ve-fold over the full BMI range. 
Smoking and drinking may aﬀ ect BMI, and, after 
adjustment for age and study, the mean BMI was slightly 
lower in current smokers than in never-smokers 
(male 0·3 kg/m², female 0·9 kg/m² lower), and in regular 
alcohol users than in others (male 0·1 kg/m², female 
1·2 kg/m² lower). Hence, in both sexes the prevalences 
of smoking and (especially in females) drinking tended 
to be high in those with low BMI (ﬁ gures 1C and 1D). In 
regular smokers or drinkers with relevant data 
(webappendix p 13), daily cigarette or alcohol con-
sumption was not strongly dependent on BMI. 
Of the 894 576 participants with baseline measurements 
of BMI, 15 996 died in the ﬁ rst 5 years of follow-up, and 
852 824 were still alive and under observation at the start 
of year 5. During 6·5 million person-years of subsequent 
follow-up (mean 8 [SD 6] years per person), 72 749 deaths 
were identiﬁ ed. Most (90%) of this additional follow-up 
and more than half (58%) of these deaths were at ages 
35–69 years; 9% of the follow-up and 29% of the deaths 
were at ages 70–79 years; and 2% and 12%, respectively, 
were at ages 80–89 years (table 1). Among the 72 749 who 
died, 54 703 (75%) were males, median year of birth was 
1918 (IQR 1910–25), and, of the 62 055 deaths for which 
the exact year of death is available, 60 153 (97%) occurred 
between 1970 and 1999 (median 1986). 6197 (9%) of the 
deaths were from an unknown cause (6% at ages 
35–69 years, 9% at 70–79 years, and 16% at 80–89 years). 
For the remainder, mean age at death was 67 (SD 10) 
years. 
In both sexes (and at all ages: webappendix p 1), all-cause 
mortality was lowest at about 22·5–25 kg/m² (ﬁ gure 2). 
All participants Never smokers only
15–25 kg/m² 25–50 kg/m² 15–25 kg/m² 25–50 kg/m²
Deaths HR (95% CI) Deaths HR (95% CI) Deaths HR (95% CI) Deaths HR (95% CI)
Overall 35 256 0·79 (0·77–0·82) 37 493 1·29 (1·27–1·32) 7054 0·87 (0·81–0·94) 9849 1·32 (1·28–1·36)
Male 26 720 0·79 (0·76–0·82) 27 983 1·32 (1·29–1·36) 3694 0·87 (0·78–0·97) 4811 1·44 (1·36–1·53)
Female 8536 0·80 (0·75–0·85) 9510 1·26 (1·23–1·30) 3360 0·87 (0·78–0·97) 5038 1·27 (1·22–1·32)
Age at risk (years)
35–59 9333 0·76 (0·71–0·81) 8386 1·37 (1·31–1·42) 1665 0·88 (0·74–1·04) 1667 1·43 (1·32–1·55)
60–69 11 514 0·77 (0·73–0·82) 13 007 1·32 (1·27–1·36) 1782 0·88 (0·75–1·03) 2841 1·36 (1·28–1·45)
70–79 10 078 0·82 (0·77–0·87) 11 358 1·27 (1·23–1·32) 2116 0·93 (0·80–1·06) 3364 1·33 (1·25–1·40)
80–89 4331 0·89 (0·80–0·97) 4742 1·16 (1·10–1·23) 1491 0·86 (0·74–1·01) 1977 1·15 (1·07–1·25)
Hazard ratio per 5 kg/m2 higher BMI (HR). HR less than 1 if BMI inversely associated with risk. All analyses exclude the ﬁ rst 5 years of follow-up and adjust for study and age at 
risk (in 5-year groups). The overall and age-speciﬁ c analyses also adjust for sex, and the all-participant analyses also adjust for baseline smoking status.
Table 1: All-cause mortality versus baseline BMI in the ranges 15–25 kg/m² and 25–50 kg/m²
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Above this minimum, mortality was on average about 
30% higher for every 5 kg/m² higher BMI. Although the 
proportional increase was somewhat greater at younger 
ages (35–59 years), each 5 kg/m² higher BMI was still 
associated with almost 30% higher mortality at 
70–79 years of age (table 1). In the lower BMI range 
(15–25 kg/m²), the inverse association of mortality with 
BMI (HR per 5 kg/m² higher BMI 0·79 [95% CI 
0·77–0·82]) became less extreme either when the analysis 
was restricted to lifelong non-smokers (0·87 [0·81–0·94]) 
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Figure 2: All-cause mortality versus BMI for each sex in the range 15–50 kg/m² (excluding the ﬁ rst 5 years of follow-up)
Relative risks at ages 35–89 years, adjusted for age at risk, smoking, and study, were multiplied by a common factor (ie, ﬂ oated) to make the weighted average match 
the PSC mortality rate at ages 35–79 years. Floated mortality rates shown above each square and numbers of deaths below. Area of square is inversely proportional to 
the variance of the log risk. Boundaries of BMI groups are indicated by tick marks. 95% CIs for ﬂ oated rates reﬂ ect uncertainty in the log risk for each single rate. 
Dotted vertical line indicates 25 kg/m² (boundary between upper and lower BMI ranges in this report).
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or when a further 10 years of follow-up were excluded 
(0·85 [0·81–0·91]; webappendix p 14).
Ischaemic heart disease accounted for more than a 
quarter of all deaths of known cause. BMI and mortality 
from ischaemic heart disease were associated strongly, 
positively, and roughly log-linearly throughout the BMI 
range from 20 to 40 kg/m², and perhaps at even greater 
BMI (ﬁ gure 3). In the upper BMI range (25–50 kg/m²), 
each 5 kg/m² higher BMI was associated with about 40% 
higher ischaemic heart disease mortality (ﬁ gure 4, 
table 2). The association was a little stronger in middle 
than in old age, but was still deﬁ nite even at ages 
80–89 years (HR 1·30 [1·17–1·45]; ﬁ gure 4A). In the 
European and Israeli studies the association was about as 
strong as it was in the US and Australian studies 
(HRs 1·38 [1·33–1·44] and 1·40 [1·32–1·50], respectively, 
for deaths at ages 35–89 years; only 44 deaths from this 
disease occurred in the Japanese studies), and there was 
no signiﬁ cant heterogeneity (p=0·13) across the HRs for 
the 16 larger studies (with >200 deaths from ischaemic 
heart disease) and the aggregated smaller studies 
(webappendix p 5).
Stroke accounted for a third as many deaths as 
ischaemic heart disease did. In the upper BMI range 
(25–50 kg/m²) each 5 kg/m² higher BMI was, as for 
ischaemic heart disease, associated with about 40% 
higher mortality (table 2), largely irrespective of follow-up 
period (after the ﬁ rst 5 years), smoking status, or stroke 
subtype (ﬁ gure 4B). As with ischaemic heart disease, 
there was no signiﬁ cant heterogeneity (p=0·64) across 
the HRs from the eight larger studies (with >100 stroke 
deaths) and the aggregated smaller studies (webappendix 
p 5). By contrast with ischaemic heart disease, however, 
the association of BMI with stroke was much stronger in 
middle than in old age (ﬁ gure 4; for both diseases, 
allowance for the older age at death of women eliminates 
the apparent relevance of sex). Furthermore, in the lower 
BMI range (15–25 kg/m²) there was no evidence of a 
positive association between BMI and stroke (ﬁ gure 3, 
table 2). Nor was there any evidence of a positive 
association in this lower range after participants who 
had ever smoked were excluded (HR 0·98 [0·78–1·23]), 
or after the analysis was restricted to haemorrhagic 
(0·76 [0·58–1·00]) or to ischaemic (0·87 [0·68–1·10]) 
stroke; the number with conﬁ rmation of subtype by 
imaging is, however, unknown.
For the aggregate of all other vascular causes of death 
(table 2), the association with BMI was similar to that for 
stroke. In the lower BMI range (15–25 kg/m²) there was, 
if anything, a slightly inverse association, but in the 
upper range each 5 kg/m² higher BMI was again 
associated with about 40% higher mortality. Among 
particular other vascular causes, the associations in the 
upper BMI range were particularly strong for mortality 
attributed to heart failure (HR 1·86 [1·55–2·23]) and to 
hypertensive disease (2·03 [1·75–2·36]).
In the upper range (25–50 kg/m²), BMI was associated 
strongly and positively with mortality attributed to 
diabetes, to non-neoplastic kidney disease, and to 
non-neoplastic liver disease (table 2), which was mainly 
cirrhosis (HR 1·79 [1·54–2·08]).
In the range 25–50 kg/m², neoplastic disease 
accounted for nearly two-thirds as many deaths as did 
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Figure 3: Ischaemic heart disease and stroke mortality versus BMI in the range 15–50 kg/m² (excluding the 
ﬁ rst 5 years of follow-up) 
Relative risks at ages 35–89 years, adjusted for age at risk, sex, smoking, and study, were multiplied by a common 
factor (ie, ﬂ oated) to make the weighted average match the PSC mortality rate at ages 35–79 years. Floated 
mortality rates shown above each square and numbers of deaths below. Area of square is inversely proportional to 
the variance of the log risk. Boundaries of BMI groups are indicated by tick marks. 95% CIs for ﬂ oated rates reﬂ ect 
uncertainty in the log risk for each single rate. 
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vascular disease, but the association with BMI was 
much weaker: only 10% higher neoplastic mortality, 
compared with 40% higher vascular mortality, for each 
5 kg/m² higher BMI (neoplastic HR 1·10 [1·06–1·15]). 
Even across the full BMI range (15–50 kg/m²) the 
95% CIs for site-speciﬁ c cancers were wide (web-
appendix p 15), but nonetheless there were positive 
associations for several sites, including the liver (HR 
1·47 [1·26–1.71]), kidney (1·23 [1·06–1·43]), breast 
(1·15 [1·02–1·31] for deaths at ages 60–89 years and, 
identically, for deaths at 35–59 years), endometrium 
(1·38 [1·08–1·77]), prostate (1·13 [1·02–1·24]), and large 
intestine (1·20 [1·12–1.28]; male 1·29 [1·19–1·40], female 
1·05 [0·94–1·18]).
In the lower range (15–25 kg/m²), BMI was associated 
inversely with mortality from cancer as a whole, mainly 
because of steep inverse associations with the cancers most 
strongly related to smoking (table 2; upper aerodigestive 
cancer includes oesophagus cancer, which had HR 0·52 
[95% CI 0·38–0·72], and cancer of the mouth, pharynx, 
and larynx). The inverse association of BMI with lung and 
upper aerodigestive cancer (combined) weakened with 
increasing duration of follow-up but was still deﬁ nite 
during years 10–14 (0·65 [0·53–0·79]) and years 15 and 
more (0·75 [0·62–0·91]). Even among life long non-smokers, 
there was a deﬁ nite inverse associa tion for upper 
aerodigestive cancer (0·35 [0·16–0·74]), although not for 
lung cancer (0·90 [0·48–1·68]).
Respiratory disease accounted for an eighth as many 
deaths as did vascular disease (table 2). In the lower range, 
BMI was strongly and inversely associated with mortality 
from each main type of respiratory disease, of which the 
most common was chronic obstructive pulmonary disease 
(COPD). After exclusion of the ﬁ rst 5 years of follow-up, 
COPD mortality in this BMI range was four times higher 
for 5 kg/m² lower BMI (HR 0·26 [95% CI 0·22–0·30]). In 
the ﬁ rst 5 years (excluded from all the main analyses), 
the inverse association at low BMI was even greater 
A B
Follow-up period (years)
0–4*
5–9
10–14
15+
*Years 0–4 are excluded
from analyses below
Age at risk (years)
35–59
60–69
70–79
80–89
Sex
Male
Female
Smoking at entry
Never smoker
Other/unknown
Current cigarette
Stroke subtype
Ischaemic
Haemorrhagic
Subarachnoid
Unclassiﬁed
All 
(BMI 25–50 kg/m2, years 5+)
2069
3291
3407
4085
2461
3904
3264
1154
8556
2227
2651
3442
4690
10 783
60·2
62·9
66·1
71·2
54·1
64·6
74·0
83·4
65·7
72·4
71·0
68·0
64·1
67·1
1·26 (1·16–1·36)
1·33 (1·24–1·43)
1·43 (1·33–1·53)
1·42 (1·34–1·51)
Trend, 4 groups: χ12=6·6 (p=0·01)
1·50 (1·39–1·62)
1·40 (1·32–1·49)
1·31 (1·23–1·40)
1·30 (1·17–1·45)
Trend, 4 groups: χ12=7·8 (p=0·005)
1·42 (1·35–1·48)
1·35 (1·28–1·43)
Heterogeneity: χ12=1·4 (p=0·2)
1·41 (1·33–1·50)
1·45 (1·36–1·54)
1·33 (1·25–1·41)
Heterogeneity: χ22=3·7 (p=0·2)
1·39 (1·34–1·44)
583
889
906
1369
463
997
1152
552
2132
1032
1062
921
1181
765
571
242
1586
3164
62·5
65·6
69·0
73·4
53·7
64·9
74·3
83·5
68·4
73·2
72·7
71·1
66·5
71·8
66·2
61·0
71·8
69·9
1·21 (1·05–1·41)
1·36 (1·20–1·54)
1·37 (1·20–1·56)
1·38 (1·24–1·53)
Trend, 4 groups: χ12=1·4 (p=0·2)
1·76 (1·52–2·04)
1·49 (1·34–1·67)
1·33 (1·19–1·48)
1·10 (0·94–1·30)
Trend, 4 groups: χ12=19·4 (p<0·0001)
1·50 (1·38–1·65)
1·30 (1·19–1·42)
Heterogeneity: χ12=5·4 (p=0·02)
1·38 (1·25–1·52)
1·47 (1·30–1·65)
1·34 (1·20–1·50)
Heterogeneity: χ22=1·2 (p=0·6)
1·38 (1·23–1·56)
1·53 (1·32–1·78)
1·19 (0·94–1·52)
1·40 (1·28–1·53)
Heterogeneity: χ32=3·2 (p=0·4)
1·39 (1·31–1·48)
Number of
deaths
Ischaemic heart disease Stroke
Number of
deaths
Mean age
at death
Mean age
at death
Hazard ratio (95% CI) for 5 kg/m2
higher baseline BMI
1 1·5 2·0 1 1·5 2·0
Hazard ratio (95% CI) for 5 kg/m2
higher baseline BMI
HR (95% CI) HR (95% CI)
Figure 4: Ischaemic heart disease (A) and stroke mortality (B) versus BMI in the upper BMI range (25–50 kg/m²) only (excluding the ﬁ rst 5 years of follow-up, except as indicated) 
Hazard ratios are per 5 kg/m²—eg, 30 kg/m² versus 25 kg/m²—and are, when appropriate, adjusted for age at risk, sex, smoking, and study. Mean ages at death are given, but the dependence of the HR 
on mean age at death is not corrected for in analyses of factors other than age. The area of each square is inversely proportional to the variance of the log hazard ratio. White squares include the ﬁ rst 
5 years of follow-up; black squares and white diamonds do not. Subarachnoid=subarachnoid haemorrhage (not included in haemorrhagic stroke).
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(0·11 [0·08–0·16]), since COPD can cause weight loss (ie, 
there is reverse causality). Exclusion of an additional 10 
years further attenuated the inverse association in the 
lower BMI range, but a strong inverse association 
remained more than 15 years after the baseline BMI 
measurement (COPD HR 0·31 [0·24–0·40]). Relatively 
few deaths were attributed to tuberculosis, which can 
cause chronic wasting and was (in the lower BMI range) 
strongly inversely associated with BMI even after 
exclusion of the ﬁ rst 10 years of follow-up (HR 0·09 [95% 
CI 0·04–0·19]). In the upper BMI range (25–50 kg/m²), 
overall respiratory mortality was about 20% higher for 
each 5 kg/m² higher BMI (table 2).
The remaining mortality was divided into three 
categories (other speciﬁ ed diseases, external causes 
[mainly injury], and unknown causes), each of which had 
a U-shaped association with baseline BMI and a minimum 
at about 22·5–25 kg/m² (table 2). For each category, 
5 kg/m² higher BMI in the 25–50 kg/m² range was 
associated with about 20% higher mortality. The other 
speciﬁ ed diseases were a broad range of disorders and 
were not dominated by any particular causes of death. 
External causes of death could not be usefully analysed, 
since little information was available about the speciﬁ c 
circumstances of these deaths.
Absolute excess mortality depends not only on relative 
risks but also on absolute mortality rates. To indicate the 
absolute excess risks at diﬀ erent BMI levels, ﬁ gure 5 is 
plotted on an additive scale and applies the PSC relative 
risks at ages 35–79 years. The absolute diﬀ erence in 
mortality between 35–50 kg/m² and 22·5–25 kg/m² was 
ﬁ ve times as great for vascular as for neoplastic disease 
in males, and twice as great for vascular as for neoplastic 
disease in females. Below 22·5–25 kg/m², there was a 
pronounced excess of lung cancer, upper aero digestive 
cancer, and respiratory disease, particularly in males 
(ﬁ gure 5).
Both in current cigarette smokers and in lifelong 
non-smokers, overall mortality was lowest at about 
22·5–25 kg/m², but the excess mortality below this 
range was both relatively and absolutely much greater 
in smokers (ﬁ gure 6, again plotted on an additive scale). 
In both smoking groups, the excess at 25–27·5 kg/m² 
was slight, and although the excess at 30–35 kg/m² was 
substantial, it was still much less than the excess 
attributable in this study to cigarette smoking itself (as 
shown in ﬁ gure 6 by the vertical separation of the curves; 
the excess attributable to persistent cigarette smoking 
throughout adult life would be even greater than this). 
Throughout the range 25–50 kg/m², the eﬀ ects of BMI 
and smoking seemed to be roughly additive, rather 
than multiplicative, both for vascular mortality 
(webappendix p 8) and for all-cause mortality (ﬁ gure 6).
Discussion
In this collaborative analysis of data from almost 
900 000 adults in 57 prospective studies, overall mortality 
was lowest at about 22·5–25 kg/m² in both sexes and at 
all ages, after exclusion of early follow-up and adjustment 
for smoking status. Above this range, each 5 kg/m² 
higher BMI was associated with about 30% higher 
all-cause mortality (40% for vascular; 60–120% for 
diabetic, renal, and hepatic; 10% for neoplastic; and 
20% for respiratory and for all other mortality) and no 
speciﬁ c cause of death was inversely associated with 
BMI. Below 22·5–25 kg/m², the overall inverse 
association with BMI was predominantly due to strong 
inverse associations for smoking-related respiratory 
disease (including cancer), and the only clearly positive 
association was for ischaemic heart disease.
In laboratory studies, BMI is moderately strongly 
correlated (30–50%) with fat-free mass, but it is much 
more strongly correlated (60–90%) with fat mass.15 BMI 
is also strongly correlated (80–85%) with measured waist 
circumference;16,17 in the EPIC prospective study of 
360 000 adults in Europe, for example, the two variables 
have about an 85% correlation, so each has a similar 
association with mortality.16 (In EPIC, waist-to-hip ratio 
was not quite as strongly related either to BMI or to 
mortality.) In such populations, either measurement can 
thus be used to help assess the causal relevance of obesity 
to mortality, and each could well add some predictive 
information to the other. Neither, however, directly 
measures visceral fat.
Although BMI and waist circumference are not directly 
causal, both are closely correlated in such populations 
with aspects of adiposity that directly aﬀ ect blood 
pressure, lipoprotein particles, and diabetes (ﬁ gure 1). 
Eﬀ ective interventions for weight loss lower blood 
15–25 kg/m² 25–50 kg/m²
Deaths HR (95% CI) Deaths HR (95% CI)
Ischaemic heart disease 7461 1·22 (1·13–1·32) 10 783 1·39 (1·34–1·44)
Stroke 2964 0·92 (0·82–1·03) 3164 1·39 (1·31–1·48)
Other vascular disease 2648 0·84 (0·75–0·95) 3396 1·47 (1·39–1·56)
Diabetes 171 0·96 (0·59–1·55) 393 2·16 (1·89–2·46)
Kidney disease (non-neoplastic) 197 1·14 (0·74–1·77) 217 1·59 (1·27–1·99)
Liver disease (non-neoplastic) 489 0·69 (0·52–0·91) 603 1·82 (1·59–2·09)
Lung cancer 2959 0·71 (0·63–0·79) 2040 0·98 (0·88–1·09)
Upper aerodigestive cancer 685 0·49 (0·39–0·61) 471 0·98 (0·79–1·20)
Other speciﬁ ed cancer 6134 0·94 (0·87–1·02) 6190 1·12 (1·06–1·18)
Respiratory disease* 2426 0·31 (0·28–0·35) 1344 1·20 (1·07–1·34)
Other speciﬁ ed disease 2049 0·62 (0·54–0·71) 1823 1·20 (1·10–1·31)
External cause 2112 0·82 (0·71–0·95) 1720 1·19 (1·08–1·32)
Unknown cause† 4961 0·72 (0·66–0·79) 5349 1·22 (1·16–1·28)
All causes 35 256 0·79 (0·77–0·82) 37 493 1·29 (1·27–1·32)
Hazard ratio per 5 kg/m2 higher BMI (HR). HR less than 1 if BMI inversely associated with risk. Analyses exclude the ﬁ rst 
5 years of follow-up, and adjust for study, sex, age at risk (in 5-year groups), and baseline smoking status. For analyses 
restricted to those who had never smoked, see webappendix p 17. *HR 0·37 (95% CI 0·30–0·44) in the range 
15–25 kg/m2 after exclusion of the ﬁ rst 15 years of follow-up (leaving 956 deaths). †Includes 4113 deaths from cancer of 
unspeciﬁ ed site.
Table 2: Cause-speciﬁ c mortality versus baseline BMI in the ranges 15–25 kg/m² and 25–50 kg/m²
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pressure, favourably aﬀ ect lipoprotein particles, and 
increase insulin sensitivity,18 and drugs that substantially 
lower blood pressure19 or LDL particle numbers20 reduce 
vascular disease. At least some of the major adverse 
eﬀ ects of obesity are, therefore, reversible.
For ischaemic heart disease, the magnitude of the 
positive association with BMI in this study can be largely 
accounted for by blood pressure, lipoprotein particles, 
and diabetes. The associations of baseline BMI with 
baseline measurements of SBP and of the non-HDL/
HDL cholesterol ratio (ﬁ gure 1) can be taken as the 
associations of BMI with the usual levels of these 
variables over the past and next few years, so they would 
predict at least a doubling of mortality from ischaemic 
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Figure 5: Mortality rates at ages 35–79 years for main disease categories versus BMI in the range 15–50 kg/m² (excluding the ﬁ rst 5 years of follow-up) 
Relative risks at ages 35–79 years, adjusted for age at risk, smoking, and study, were multiplied by a common factor (ie, ﬂ oated) to make the weighted average match the age-standardised European 
Union (15 countries) mortality rate at ages 35–79 years in 2000. Neoplastic mortality is split into the types most strongly associated with smoking (cancers of the lung and upper aerodigestive tract) 
and all other speciﬁ ed types. By contrast with ﬁ gures 2–4, risk is indicated on an additive rather than multiplicative scale, with ﬂ oated mortality rates shown above or below each symbol. The estimates 
for 35–50 kg/m² are based on limited data, so lines connecting to those estimates are dashed. Boundaries of BMI groups are indicated by tick marks. 95% CIs for ﬂ oated rates reﬂ ect uncertainty in the 
log risk for each single rate. 
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heart disease between 20 kg/m² and 30 kg/m² (if the 
combined eﬀ ects of SBP and the ratio of cholesterol 
fractions were approximately additive10,11), which is what 
was observed. (Merely adjusting regression analyses for 
single measurements of blood pressure and total 
cholesterol would underestimate the mediating eﬀ ects 
of blood pressure and, especially, of lipoprotein 
particles.21,22) Above 30 kg/m², further increases in BMI 
have little further eﬀ ect on the ratio of cholesterol 
fractions (ﬁ gure 1B), but could be associated with other 
adverse changes in lipoprotein particles that cannot be 
inferred from cholesterol fractions (eg, an increase in 
the number of small dense LDL particles). Diabetes 
becomes particularly important at BMI greater than 
30 kg/m² (ﬁ gures 1C and 1D). Other hypothesised 
intermediate factors (eg, ﬁ brinogen, C-reactive protein, 
obstructive sleep apnoea) were not assessed.
Confounding by diet, physical activity, or socio-
economic status could have somewhat aﬀ ected the 
ischaemic heart disease results. The cardioprotective 
eﬀ ects of physical activity might not be due solely to 
reduced adiposity,23 so variation in physical activity 
could have caused the independent eﬀ ects of adiposity 
to be somewhat overestimated. Confounding by 
socioeconomic status could have caused the independent 
eﬀ ects to be either overestimated or underestimated. In 
the three prospective studies of US health professionals, 
however, there would have been relatively little 
socioeconomic confounding, yet for all-cause mortality 
in the upper BMI range (there were too few deaths to 
subdivide by cause), the association seemed to be 
broadly similar across these three studies to that in the 
PSC as a whole (webappendix p 14).
The weakening of the association between BMI and 
mortality from ischaemic heart disease above age 
70 years is probably a result of the weaker associations 
at older ages of blood pressure and cholesterol with 
risk,10,11 and the slightly weaker associations of BMI with 
these intermediate variables. (At older ages, BMI might 
depend increasingly on muscle loss.24)
For stroke, the ﬁ ndings in the upper and lower BMI 
ranges were quite diﬀ erent from each other. In the 
upper range, BMI was associated positively with 
ischaemic, haemorrhagic, and total stroke, and each of 
these associations can be largely accounted for by the 
eﬀ ects of BMI on blood pressure. In the lower BMI 
range, however, there was no evidence of a positive 
association for ischaemic, haemorrhagic, or total stroke, 
despite the strong positive association between BMI and 
blood pressure. (For a speciﬁ c blood pressure, therefore, 
BMI in this lower range would actually be inversely 
related to stroke.) These ﬁ ndings for stroke in the lower 
BMI range were not materially aﬀ ected by exclusion of 
participants who had ever smoked (by contrast with the 
ﬁ ndings reported from a large Chinese prospective 
study25). The evidence from previous large studies of 
BMI and stroke subtype is not as consistent as might be 
expected,1,3,26–28 but generally suggests that the association 
of BMI with stroke risk is strongly positive at BMI 
greater than 25 kg/m² for both ischaemic and 
haemorrhagic stroke, and, less deﬁ nitely, that at BMI 
less than 25 kg/m² it is still positive for ischaemic but 
not for haemorrhagic stroke. In the lower BMI range, 
however, the PSC found no evidence of an association 
for ischaemic stroke (although the possibility of a weak 
positive association is not excluded), and found only 
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Figure 6: All-cause mortality at ages 35–79 years versus BMI in the range 15–50 kg/m², by smoking status 
(excluding the ﬁ rst 5 years of follow-up) 
Relative risks at ages 35–79 years, adjusted for age at risk, sex, and study, were multiplied by a common factor 
(ie, ﬂ oated) so that the mean for all participants (including ex-smokers and anyone with missing smoking data) 
matches the European rate at ages 35–79 years in 2000. Results for ex-smokers and those with missing smoking 
data not shown (but are, taken together, only slightly above those for never smokers). Note that many smokers 
were at only limited risk, since they had not smoked many cigarettes during early adult life, or had stopped shortly 
after the baseline survey. Risk is indicated on an additive rather than multiplicative scale. The estimates for 
35–50 kg/m² are based on limited data, so lines connecting to those estimates are dashed. Floated mortality rates 
shown above each square and numbers of deaths below. Area of square is inversely proportional to the variance of 
the log risk. Boundaries of BMI groups are indicated by tick marks. 95% CIs for ﬂ oated rates reﬂ ect uncertainty in 
the log risk for each single rate.
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slight evidence of an inverse association for haemor-
rhagic stroke. These ﬁ ndings for stroke in the lower 
BMI range are not fully explained.
For kidney and liver disease,8,9 the positive associations 
with BMI could have resulted mainly from the eﬀ ects of 
adiposity on blood pressure, diabetes, and blood lipids. 
Central adiposity can cause non-alcoholic fatty liver 
disease, which could predispose to cirrhosis or 
hepatocellular carcinoma (the commonest type of liver 
cancer).9 The positive associations of BMI with cirrhosis 
and liver cancer are unlikely to have been due to 
confounding by alcohol, since drinking was not strongly 
related to BMI in males and was inversely related to it in 
females.
For cancer, the evidence of several positive associations 
complements that from other million-person prospective 
studies (eg, the Cancer Prevention Study-II4 and the 
Million Women Study5). Possible mechanisms by which 
obesity could cause cancer at particular sites have been 
summarised elsewhere.29 The overall inverse asso cia tion 
with cancer mortality in the lower BMI range 
(15–25 kg/m²) was mainly due to inverse associations 
with cancers of the lung and oesophagus. Most of the 
oesophageal cancer deaths occurred before the 1990s, so 
most are likely to have been squamous cell carcinomas,30 
which are reported to be associated inversely with BMI, 
rather than adenocarcinomas, which are reported to be 
associated positively:5,31 histological subtype is, however, 
not available in the PSC. The inverse association for lung 
and upper aerodigestive cancer combined was still 
strongly negative even after exclusion of the ﬁ rst 10 years 
of follow-up, implying that it was not chieﬂ y a result of 
reverse causality.
For COPD and other respiratory diseases, the inverse 
associations with BMI in the range 15–25 kg/m² were 
remarkably strong. In each sex, the inverse association 
for respiratory mortality accounted for about 60% of the 
diﬀ erence in all-cause mortality between 15–20 kg/m² 
and 22·5–25 kg/m² (ﬁ gures 2 and 5). COPD can cause 
weight loss over many years, so the inverse association 
(even after exclusion of the ﬁ rst 15 years of follow-up) 
might have been due mainly to reverse causality (ie, to 
low BMI being an indicator of progressive COPD). 
However, some close correlate of low BMI itself could 
increase COPD progression and, hence, mortality.
The inverse associations with COPD, lung cancer, 
and upper aerodigestive cancer were much steeper in 
smokers than in non-smokers. Smoking is a major 
cause of all three diseases, and the greater steepness in 
smokers might have been due at least partly to 
uncontrolled confounding by smoking intensity. 
Smoking can cause weight loss,32 and if greater intensity 
of smoking were to cause increased weight loss, then 
there would be a substantially greater proportion of 
intensive smokers in the lower BMI categories, who 
would be at greater risk of these conditions (both 
through direct eﬀ ects and, possibly, as a result of being 
less likely to quit). Although cigarettes smoked per day 
varied little with BMI in this study, other evidence 
(webappendix p 13) suggests that, for a speciﬁ c number 
of cigarettes per day, leaner smokers have substantially 
higher blood cotinine concentrations than other 
smokers do (and also substantially more lung cancer, 
upper aerodigestive cancer, and COPD). Hence, 
smoking intensity might confound associations with 
BMI even in the absence of an association between BMI 
and daily cigarette consumption. Alternatively, lower 
BMI might somehow exacerbate the eﬀ ects of smoking 
on respiratory cancer or other respiratory disease. The 
steep inverse associations for these diseases among 
smokers are still largely unexplained.
This study did not assess measures of central obesity, 
but other large epidemiological studies have done so. 
In the ten-country EPIC prospective study (with 
12 000 deaths of known cause, of which 3000 were 
vascular [vs 36 000 vascular deaths in the PSC]),16 waist 
circumference improved the ability of BMI to predict 
vascular and all-cause mortality. In the 52-country 
INTERHEART case–control study of acute myocardial 
infarction (with 12 000 cases),33 a diﬀ erence of 5 kg/m² 
in BMI seems, for reasons that are not clear, to be of 
much less relevance to heart disease (odds ratio ~1·12 
[95% CI 1·08–1·16]) than it was in the PSC (HR 1·39 
[1·34–1·44]) or in EPIC (HR ~1·4), and hence to be of 
much less relevance than measures of central obesity 
are. Since case–control studies have greater potential 
for some types of bias, disentangling the interdepen-
dent associations of closely correlated anthropometric 
variables with particular diseases might need 
prospective studies that are even larger than this PSC 
study.
This report cannot quantify the eﬀ ects of present 
levels of childhood obesity on adult mortality over the 
next few decades; the relevance of obesity to mortality 
in diﬀ erent ethnic groups; the substantial eﬀ ects of 
obesity on disability, quality of life, or non-fatal disease 
(eg, osteoarthritis, obstructive sleep apnoea); or the 
positive eﬀ ects of some types of adiposity on prognosis 
after some chronic disorders (eg, heart failure,34 
respiratory disease35) have already developed. It does, 
however, quantify particularly reliably both the excess 
mortality associated with low BMI (much of which 
could be non-causal) and that associated with high BMI 
(which would be even greater if full allowance could be 
made for the extent to which chronic disease can cause 
weight loss). If the overall inverse association at low 
BMI is partly non-causal, then the real optimum BMI 
might be somewhat lower than the apparent optimum 
of about 23 kg/m² or 24 kg/m².
The absolute excess mortality at BMI greater than 
22·5–25 kg/m² was mainly vascular, but also partly 
neoplastic, and was probably largely causal (ie, due to 
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causal factors closely associated with BMI). Figure 7 
shows, for diﬀ erent BMI levels in middle age, estimates 
of the lifetime probabilities of surviving from age 
35 years, which are calculated by applying the relative 
risks that were considered likely to be causal 
(webappendix p 18) to disease-speciﬁ c mortality rates at 
ages 35–79 years from the EU in 2000.13 (The year 2000 
EU probability of surviving from birth to age 35 years 
is 98%.) For both sexes, the median survival (ﬁ gure 7A) 
is reduced by 0–1 year for people who would, by about 
age 60 years, reach a BMI of 25–27·5 kg/m², by 1–2 years 
for those who would reach 27·5–30 kg/m², and by 
2–4 years for those who would become obese 
(30–35 kg/m²). Much less information was available for 
BMI greater than 35 kg/m² (hence the dashed lines in 
ﬁ gure 7B), but the median survival seems to be reduced 
by about 8–10 years in those who would become 
morbidly obese (40–50 kg/m², which in the PSC is mainly 
40–45 kg/m²).
The extreme reduction in survival with morbid obesity 
is about as great as the 10-year reduction caused by 
persistent cigarette smoking in male British doctors born 
in 1900–30, for whom the cigarette smoker versus 
non-smoker mortality rate ratio was about 2·5 not only at 
35–69 years but also at 70–79 years of age.13,36 In the present 
report, the smoker versus non-smoker mortality rate ratio 
is slightly less than 2·5 for men aged 35–69 years, and 
much less than 2·5 for women aged 70–79 years 
(webappendix p 7). In both cases this was partly because 
many who were current smokers at baseline did not 
smoke as many cigarettes when young as the British 
doctors did (or, indeed, as young smokers do nowadays), 
B
A
4035 50 60 70
76
49
18
1
91
77
50
15
88
95
72
40
5
88
70
31
80 90 1004035 50 60 70 80 90 100
Age (years) Age (years)
BMI range (kg/m2)
BMI range (kg/m2)
Yearly dots
Yearly dots
Yearly dots
22·5–25 (mean 24)
25–30 
30–35 (mean 32)
35–40
40–50 (mean 43)
Male
3 main and 2 higher BMI categories
Female
Yearly dots
22·5–25 (mean 24)
25–30 (mean 27) 
30–35 (mean 32)
Male
3 main BMI categories
Female
91
77
50
15
87
69
39
8
95
88
70
31
94
84
61
19
80
60
40
20
0
0
Al
iv
e 
(%
)
80
60
40
20
Al
iv
e 
(%
)
100
100
Figure 7: BMI versus lifespan in western Europe, year 2000
Estimated eﬀ ects of the BMI that would be reached by about 60 years of age on survival from age 35 years, identifying European Union (EU) mortality rates in 2000 
with those for BMI 25–30 kg/m² and combining the disease-speciﬁ c EU mortality rates with disease-speciﬁ c relative risks (for details, see webappendix pp 18–20). The 
absolute diﬀ erences in median survival (but probably not in survival to age 70 years) should be robust to changes in mortality rates, and therefore generalisable 
decades hence. (A) 3 main BMI categories. (B) 3 main and 2 higher BMI categories. (The 2 higher BMI categories account for just 2% of PSC participants, and so are 
indicated by dashed lines.) 
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and partly because many who were current smokers at 
baseline in the PSC would have quit during follow-up 
(which is taken account of in the doctors’ study,36 but not 
in the PSC). The diﬀ erence in mortality between smokers 
and non-smokers in ﬁ gure 6 therefore underestimates the 
eﬀ ects of smoking throughout adult life, but it could 
likewise underestimate the eﬀ ects of becoming obese well 
before middle age.
These PSC relative risks for BMI, combined with recent 
population BMI values,37,38 suggest that in the present 
decade, about 29% of vascular deaths and 8% of neoplastic 
deaths in late middle age in the USA (where mean BMI6 
at age 50 years was 28·5–29 kg/m² in 2000) would have 
been attributable to having a BMI greater than 25 kg/m²; 
for the UK (where mean BMI38 at that age was about 
1 kg/m² lower), the corresponding proportions would 
have been about 23% and 6%, respectively. In both 
countries, as elsewhere, these proportions will probably 
increase if average BMI in middle age continues to rise, 
even if rates of vascular and neoplastic mortality 
continue to fall because of decreases in smoking, 
improvements in treatment, or other reasons. Moreover, 
since BMI is an imperfect measure of visceral and other 
adiposity, the number of vascular and other deaths 
attributable to all adiposity-related factors is probably 
appreciably greater than these calculations suggest.
In adult life, it may be easier to avoid substantial 
weight gain than to lose that weight once it has been 
gained. By avoiding a further increase from 28 kg/m² to 
32 kg/m², a typical person in early middle age would 
gain about 2 years of life expectancy. Alternatively, by 
avoiding an increase from 24 kg/m² to 32 kg/m² (ie, to 
a third above the apparent optimum), a young adult 
would on average gain about 3 extra years of life.
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